Cencora, Inc. $COR Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System lowered its stake in shares of Cencora, Inc. (NYSE:COR) by 11.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 682,122 shares of the company’s stock after selling 84,384 shares during the period. California Public Employees Retirement System’s holdings in Cencora were worth $204,534,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC lifted its position in shares of Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after acquiring an additional 35 shares during the period. Vermillion & White Wealth Management Group LLC increased its stake in Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after purchasing an additional 43 shares in the last quarter. Twin Peaks Wealth Advisors LLC purchased a new position in Cencora in the 2nd quarter valued at approximately $52,000. Caitong International Asset Management Co. Ltd acquired a new position in Cencora during the second quarter worth $61,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in Cencora during the second quarter worth $61,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Trading Up 0.5%

Shares of COR stock opened at $339.28 on Monday. The firm has a 50-day moving average price of $340.04 and a 200 day moving average price of $309.73. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $377.54. The company has a market capitalization of $65.82 billion, a price-to-earnings ratio of 42.68, a PEG ratio of 1.61 and a beta of 0.63. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. The company had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period last year, the company earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio (DPR) is 30.19%.

Insider Activity at Cencora

In other news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the sale, the chief executive officer owned 65,746 shares in the company, valued at $24,105,113.44. This trade represents a 7.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 46,640 shares of company stock valued at $14,099,338 over the last ninety days. 10.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on COR. UBS Group raised their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Mizuho raised their target price on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Weiss Ratings cut shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, December 1st. Wells Fargo & Company upped their price target on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Finally, JPMorgan Chase & Co. increased their price target on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $371.09.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.